New Frontiers in Nephrotic Syndrome in Children

Bharat J Parmar *

Department of Pediatrics, BJ Medical College, Civil Hospital Ahmedabad, Gujarat, India

Submission: November 25, 2016; Published: August 30, 2017

*Corresponding author: Bharat J Parmar, Department of Pediatrics, BJ Medical College, Civil Hospital G-103 Shilalekh Opp. Police Stadium Shahibaug Ahmedabad 380004, Gujarat, India, Tel: 9825613362 Email: bjpdr@hotmail.com

Abstract

The commonest type of Nephrotic Syndrome in Children is Idiopathic Nephrotic Syndrome (90%) & are called “Minimal Change Nephrotic Syndrome”. Minimal Change Nephritic Syndrome (MCNS) is unique among other varieties in that despite dramatic clinical expression the kidney shows either minimal or no change on light or immune fluorescent microscopy. Hallmark of MCNS are generalised anasarca, massive proteinuria, (>2mg/day or >40mg/24hr) hypoalbuminemia S. Albumin (<2.5mg/Dl), hypercholesterolemia S. Cholesterol>200mg/dL. It is auto immune disease with frequent remission & relapse.

Keywords: Minimal change nephrotic syndrome (MCNS); Steroid dependant syndrome (SDNS); Frequently relapsing nephritic syndrome (FRNS); Comprehensive management

Introduction

Clinical expressions

Gradual onset of oedema on face more in the morning then spread to whole body in next few day. Development of generalised anasarca, ascites, marked oedema of genitals. No fever and blood pressure is normal. Nephrotic range of proteinuria is documented with early morning urine protein 3 + or 4 + on dipstick or turbidometry method, spot urine protein/creatinine ratio>2mg/mg and urine albumin excretion >40mg/m²/hr on a timed-sample. As per Indian Society of Pediatric Nephrology (ISPN) guidelines, precise quantitative assessment of proteinuria is seldom necessary.

Idiopathic nephritic syndrome is histologically characterized by minimal change disease, Focal and Segmental Glomerulo Sclerosis (FSGS) & diffuse mesangial proliferation. Idiopathic nephrotic syndrome is most common (90%) various other causes associated with NS. Infections like malaria, hepatitis B, Hepatitis C, Systemic diseases SLE & HSP one of the hematological disease Thalasemia major diabetes mellitus.

Pathogenesis

Idiopathic nephrotic syndrome occur as a result of immunological dysfunction. Recently according to new theory proteinuria is as result of molecular mechanism of glomerular filtration barrier. One of the essential component of glomerular basement membrane i.e. podocyte plays a main role in filtration mechanism. The multiprotein complex between adjacent podocyte process, the slit diaphragm, is essential for the control of the act in cytoskeleton and cell morphology of podocyte. Genetic mutation encoding podocyte and slit diaphragm proteins nephrin, podocin, transient receptor potential-6 channel, Wilms’ tumor 1 gene and alpha-actinin-4 have identified by genetic studies of inherited nephrotic syndrome. Circulating permeability factors like IL-13 and Nuclear Factor Kappa b (NF-Kb) which alters the glomerular filtration barrier can cause proteinuria. Finally the response to rituximab in nephrotic syndrome, suggest role for B cell involvement and/or B cell-T Cell cross talk in causation of nephrotic syndrome.

Oedema in nephrotic Syndrome

Oedema is a classical expression of nephrotic syndrome. The undrfill hypothesis state that decrease in oncotic pressure leads to excess filrerate of the fluid from intravascular space to the interstitial space causing hypovolemia, renal hypoperfusion activate rennin angiotensin aldosterone systean and secondary renal sodium retension.

Overfill hypothesis nephrotic proteinuria causes primary renal sodium retension lead in to oedema. Recently proposed mechanism of sodium retention regardless of intravascular volume status and it is due to the activation of epithelial sodium channel by serine proteases in the glomerular filtrate of nephrotic syndrome.
patient. Plasminogen filtered by the nephrotic glomeruli is converted to plasmin by urokinase-type plasminogen activator in the cortical collecting duct cells. Plasmin then proteolytically removes the inhibitory domain from epithelial sodium channel (ENaC), resulting in near full activation of ENaC. Other proposed mechanism of oedema formation include (a) increased angiotensin ii independent afferent and efferent arteriolar tone because of the increased efferent sympathetic nervous activity, (b) tubular resistance to atrial natriuritic peptide and (c) increased number and activity of cortical collecting duct Na/K ATP as e-channel.

Assessment of Nephrotic Syndrome

a. Initial: Height, weight and Blood pressure

b. Physical examination: Severity of oedema, focus of sepsis, signs of systemic illness, hepatosplenomegaly, pallor, skin rash, arthritis.

c. Investigation: Urine, CBC, Renal function tests, S. Albumin, S. Cholesterol, Manutox test, ESR, X-ray chest, USG Abdomen, S. Complement C3, C4. During October 2016 Two patients of nephrotic syndrome admitted in my institute i.e. Nephrotic syndrome & Thalassemia major, Nephrotic syndrome & Diabetes mellitus as Steroid toxicity. First Patient presented as Nephrotic syndrome with Thalassemia major. Patient named Himanshu aged 3 year old with clinical expressions: Generalised oedema, anorexia, pallor, Urine protein 3+ 4+, S. albumin 1.5g/Dl, S. cholesterol 394 mg/Dl, Blood urea & S. creatinine are normal. O/E Blood pressure normal, Anemia, Hepatosplenomegaly, haemolytic face X-ray Skull widen deploic space thinner outer table skull (Figure 1-3).

Second patient named Sakhi Vikrambhai Parmar aged 5.5 year presented as Diabetes mellitus due to steroid toxicity with clinical expressions: Polyuria, breathlessness, vomiting Diabetic ketoacidosis, Blood sugar 450mg/Dl, ketonuria and ketonemia. Past history Nephrotic syndrome diagnosed at age of 1 year and treated with steroids and immunomodulator for 4 time In next 1 year. Steroids stopped since 8 months (Figure 4).
Comprehensive management

Supportive management: Adequate protein (1.5-2mg/kg) and calories. Salt restriction (1-2gm/day) with persistent oedema. Fluid restriction if necessary in massive oedema. Supplementation of calcium and vitamin D. Immunization. Pneumococcal vaccine does not give live vaccines. Measles, MMR, Chicken pox chil receiving high doses of steroids. Growth monitoring weight and height. Parents should be told about importance of early treatment of inter current infection and indication of admission. Ensure compliance regarding medication encourage physical activity and play activity.

Diuretics: In nephrotic syndrome induction of Na, K- ATP as e-channel there increase in sodium reabsorption there by reducing natriuretic effect of furosemide. This can be corrected by co-administration of amiloride which inhibits the distal sodium reabsorption by blocking the ENaC channels and there by overcome furosemide resistance. Use combination furosemide and thiazide or furosemide and amiloride. It is also considered in resistant oedema. Continuous infusion of the loop diuretics has greater diuretic potency then intermittent therapy. In refractory oedema, 20% albumin infusion (1gm/kg) can be tried. It is ideal to give furocimedit at the end of infusion for to prevent pulmonary oedema thus plasma volume expansion with IV Albumin might play an adjunctive role in diuretic management.

Specific management: The ultimate goal of our long term management is to induce the remission; maintain it and at the same time minimize side effects of medications. Nephrotic Syndrome should be treated adequately with corticosteroids, both in terms of dose and duration, which is an important determinant of long term course of the disease. Initial dose of nephrotic syndrome should be treated with prednisolone 2mg/kg per day (maximum 60 mg /day) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg /day) as single morning dose on alternate days for the next 6 weeks followed by tapering over 2 to 4 weeks. Child dose not go to remission with 4 weeks daily steroid therapy designated as steroid resistant nephrotic syndrome.

Relapse of nephrotic syndrome always look for precipitating factor, which most often is an infection. Adequate treatment of infection may result in spontaneous remission. Relapse is treated with prednisolone 2mg/kg/day until urine protein is trace or nil for three consecutive days. Subsequently prednisolone is given in single morning dose of 1.5mg/kg on alternate day for 4 weeks and then discontinued.

Role of steroid sparing drugs in nephrotic syndrome

a. Levamisole: Frequent relapse NS & Steroid dependant NS where the steroid threshold is high ideal treatment is Levamisole. It is immune modulator. Dose 2 to 2.5mg/kg on alternate days 12 to 24 months along with Prednisolone 1.5mg/kg on alternate day to start with, gradually tapering it to a maintenance dose 0.20 to 0.25mg/kg continued for 6 to 12months. Levamisole is used to achieve a steroid sparing effect, ideally to started after inducing remission. Monitor WBC every 12 to 16 weeks.

b. Cyclophosphamide: Indication of use of this cytotoxic alkylating agent for FRNS & SDNS. 2 to 2.5mg/kg/day for 12 weeks orally or IV monthly pulses of 6 doses ensuring that cumulative dosage does not exceed 168 mg/kg/per course. It should be start preferably after remission of proteinuria in FRNS & SDNS. Prednisolone is co-administered for 6 to 12 months. Monitoring WBC for leucopenia every 2 weeks.

c. Mycophenolate mofetil (MMF): It is an antiproliferative agent that inhibits T & B lymphocyte proliferation by inhibition of inosin monophosphate dehydrogenase which is key enzyme in Perine biosynthesis. Dose 800 to 1200 mg/kg/m in 2 divided doses along with tapering dose of prednisolone for 12 to 24 months. Monitor WBC for leucopenia every 1-2 months.

d. Calcineurine inhibitors (CNI): 5mg/kg for 12-24 months. Tacrolimus .1 to .2mg/kg daily for 12-24 months. Prednisolone is co-administered and tapered to a loe maintenance .25 - .5mg/kg continued for 6 or more months. It is indicated when no response of Levamisole, cyclophosphamide and MMF in SRNS AND difficult SDNS. Tacrolimus is preferred over cyclosporine in view of lack of cosmetic side effects like hirsutism, ginivalhyperplasia which is seen in cyclosporine.

e. Rituximab: It is novel genetically engineered anti-CD20 monodonal antibody that selectively targets CD20-Positive B cells. Mechanism of this drug in NS are restoration of T-Regulatory (T REG) cell population and/or up regulation of their function and decreasing proteinuria. It inhibit the production of cytokines, surpasses the circulating permeability factor. Rituximab is very effective in difficult SDNS and SRNS not responding to CNI’s. Dose is 375 mg /week for 2 or more doses to achieve CD19 level below 1 % of leucocyte. Side effects of drug are hypotension or hypertension, flu like symptoms and risk of infection.

i. Complications

a. Infections: Prone to develop primary peritonitis and systemic infection due to urinary loss & inefficient production of immune globulins, defective cell mediated immunity and use of immune suppressive drugs.

b. Hyperlipidemia: It may be due to increases hepatic synthesis of lipoproteins secondary to hypoalbuminema. Hyperlipidemia may lead to platelet aggregates and risk of renal vein thrombosis.

c. Electrolyte disturbances: Hyponatrimia, hyperkalemia and hypocalcemia. Hypocalcemia as result of reduction of protein bound calcium secondary to hypoalbuminema, urinary loss of D-binding globulin, 25-hydroxyvitamin D3 and further aggravated by prolonged corticosteroids therapy.

d. Acute renal failure: It is due to intrinsic glomerular damage in atypical nephrotic syndrome. These patient are very sensitive
to reduction of blood volume. As result of diarrhea, vomiting or rapid diuresis they cal develop hypovolemic shock and pre renal azotemia promptly managed by administration of albumin or plasma to prevent renal dysfunction.

ii. **Key massages:** Most common causen nephrotic syndrome in children is idiopathic nephrotic syndrome. Though it is called idiopathic, various pathogenetic mechanisms for proteinuria include deregulation of T cells, genetic mutation, circulating permeability factors and aberrant cross talk between B & T cell. Overfill hypothesis of oedema formation is supported by activation of tubular ENaC. Nephrotic oedema should be treated cautiously with appropriate diuretics either alone or combination with serial monitoring of electrolytes and other adverse effects. Nephrotic syndrome should be treated adequatly with corticosteroids both in terms of dosage and duration. In case of relapse, adequate treatment of infection may result in spontaneous remission. Loe dose of steroids is always co-administered with steroids sparing drugs in the initial period of treatment of FRNS and SDNS. All steroids sparing drugs have their own benefits and adverse effects. Hence serial monitoring to look for adverse effects should be stressed. Rituximab, a novel genetically engineered anti CD20 monoclonal antibody which selectively targets CD20-positive B cells is useful in difficult SDNS and SRNS. Patients of nephrotic syndrome should be counselled regarding the need for pneumococcal vaccination when the children in remission. In children with risk of suppression hypothalampitutory adrenal axis should get stress dose of steroids during period of stress if they have received steroids in the past one year. Complications due to disease and drugs per say should be addressed as early as possible in children with nephrotic syndrome to prevent the adverse consequences.

**Acknowledgement**

The Author wish to thank BJ. Medical College, Civil Hospital Ahmadabad for support this work.

**References**


This work is licensed under Creative Commons Attribution 4.0 License
DOI: 10.19080/AJPN.2017.05.555726

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php

How to cite this article: Bharat J P. New Frontiers in Nephrotic Syndrome in Children. Acad J Ped Neonatol. 2017; 5(4): 555726.
DOI: 10.19080/AJPN.2017.05.555726.